← back to search

Michael A. Caligiuri

City Of Hope National Medical Center · US
Area of research
Immunology · Hematology
Research interest
Research interests include Immune Cell Function and Interaction, Acute Myeloid Leukemia Research, Virus-based gene therapy research, and CAR-T cell therapy research.
h-index
135
citations
70,220
works
865
NIH funding
primary concept
Medicine
email

Recent publications

Human pluripotent stem cell-derived innate and adaptive immune cells for cancer immunotherapy.
2026cited by 0position: contributordoi
No BCMA? No Problem: A CD70-Targeting CAR-NK Cell Shows Promise in High-risk Myeloma.
2026cited by 0position: contributordoi
Human type-1 innate lymphoid cells control leukemia stem cell differentiation and limit acute myeloid leukemia development.
2026cited by 0position: contributordoi
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy.
2026cited by 0position: contributordoi
Interim report on engineered NK cell trial in lung cancer refractory to immune checkpoint inhibitors
JCI Insight 2025cited by 10position: contributordoi
Loss of YTHDF2 enhances Th9 programming and CAR-Th9 cell antitumor efficacy.
2025cited by 5position: contributordoi
CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors
Journal of Clinical Investigation 2025cited by 4position: contributordoi
Off-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice.
2025cited by 3position: contributordoi
miR-142 deficit in T cells during blast crisis promotes chronic myeloid leukemia immune escape.
2025cited by 3position: contributordoi
Comparative efficacy and safety of PSCA CAR-engineered Vδ1 γδ T cells for immunotherapy of pancreatic cancer.
2025cited by 1position: contributordoi
NKp46 enhances type 1 innate lymphoid cell proliferation and function and anti-acute myeloid leukemia activity.
2025cited by 1position: contributordoi
Therapeutic application of human type 2 innate lymphoid cells via induction of granzyme B-mediated tumor cell death
Cell 2024cited by 91position: middledoi
Human anti-PSCA CAR macrophages possess potent antitumor activity against pancreatic cancer.
2024cited by 64position: contributordoi
The tumor-intrinsic role of the m <sup>6</sup> A reader YTHDF2 in regulating immune evasion
Science Immunology 2024cited by 51position: middledoi
Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
2024cited by 9position: contributordoi
Supplementary Figure S1 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Table S1 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S4 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Data from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S5 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S2 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S4 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S1 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S5 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S6 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S2 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Table S1 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S3 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Data from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi
Supplementary Figure S6 from Preclinical Evaluation of Off-The-Shelf PD-L1&lt;sup&gt;+&lt;/sup&gt; Human Natural Killer Cells Secreting IL15 to Treat Non–Small Cell Lung Cancer
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 100 papers (2020–2026)Jianhua Yu · Chung Shan Medical University36 papers (2021–2026)Balveen Kaur · The University of Texas Health Science Center at Houston34 papers (2022–2023)Yuqing Chen · City of Hope34 papers (2022–2023)Jianying Zhang · Inner Mongolia Agricultural University26 papers (2015–2024) · 22 papers (2022–2026) · 20 papers (2021–2024)Zhenlong Li · City Of Hope National Medical Center19 papers (2024–2026) · 18 papers (2021–2024) · 18 papers (2024–2025) · 17 papers (2024–2024) · 17 papers (2024–2024)Rui Ma · City Of Hope National Medical Center17 papers (2024–2024) · 17 papers (2024–2024)Christian Bustillos · University of California, Los Angeles17 papers (2024–2024)Zhiyao Li · City Of Hope National Medical Center17 papers (2024–2024)Miguel A. Villalona‐Calero · University of California, Irvine17 papers (2024–2024)Tasha Barr · University of California, Irvine15 papers (2021–2025)Jianhua Yu · University of California, Irvine12 papers (2012–2024)Ansel Nalin · The University of Texas MD Anderson Cancer Center11 papers (2020–2023)